Published
{
"ticker": "SNY",
"cik": "0001121404",
"company": "Sanofi",
"business_type": "pharmaceutical",
"schema_template": "standard (pharmaceuticals, IFRS): net sales and other revenues, gross profit, operating income, net income from continuing and discontinued operations, net income attributable to equity holders of Sanofi, EPS; balance sheet with Sanofi's own debt and net-debt totals; cash flow; Sanofi's own non-IFRS 'business' measures and free cash flow kept in a separate block. Net sales is Sanofi's headline top line.",
"reporting_currency": "EUR",
"converted_to_usd": true,
"units": "actual US dollars (not millions), converted from euros; per-share figures are per American Depositary Share (one ADS represents one-half of one ordinary share); share counts are ordinary shares as filed",
"units_notes_seen": {
"FY2025 Form 20-F consolidated income statements": "(\u20ac million) | Note | 2025 | 2024 | 2023 (a); share counts 'Average number of shares outstanding (million)'; EPS rows '(\u20ac)'",
"FY2025 Form 20-F consolidated balance sheets": "(\u20ac million) | Note | December 31, 2025 | December 31, 2024 | December 31, 2023",
"FY2025 Form 20-F consolidated statements of cash flows": "(\u20ac million) | Note | 2025 | 2024 | 2023 (a)",
"FY2025 Form 20-F note D.17.1 (debt, cash and cash equivalents)": "(\u20ac million) | 2025 | 2024 | 2023",
"FY2025 Form 20-F consolidated statements of changes in equity": "(\u20ac million); dividend per share stated in the row caption in euros",
"H1 2026 condensed consolidated income statements": "(Unaudited) (\u20ac million) | Note | June 30, 2026 (6 months) | June 30, 2025 (6 months); EPS rows '(\u20ac)'",
"H1 2026 note B.8.7 (earnings per share)": "(number of shares in million) | June 30, 2026 (6 months) | June 30, 2025 (6 months)",
"H1 2026 condensed consolidated balance sheets": "(Unaudited) (\u20ac million) | Note | June 30, 2026 | December 31, 2025",
"H1 2026 condensed consolidated statement of cash flows": "(Unaudited) (\u20ac million) | Note | June 30, 2026 (6 months) | June 30, 2025 (6 months)",
"H1 2026 note B.9 (debt, cash and cash equivalents)": "(\u20ac million) | June 30, 2026 | December 31, 2025",
"H1 2026 condensed consolidated statements of changes in equity": "(Unaudited) (\u20ac million); dividend per share stated in the row caption in euros",
"Q2 2026 press release Appendix 3 (consolidated income statement)": "(\u20ac million) | Q2 2026 | Q2 2025 | H1 2026 | H1 2025; 'Average number of shares outstanding (million)'; EPS rows '(\u20ac)'",
"Q2 2026 press release Appendices 2 and 4 (business net income)": "(\u20ac million) | Q2 2026 | Q2 2025 | ...; 'Business EPS (in euros)'",
"Q2 2026 press release Appendix 5 (net debt and summarised cash flow)": "(\u20ac million) | H1 2026 | H1 2025",
"Q2 2026 press release sales tables": "Net sales (\u20ac million) | Q2 2026 | Change at CER | H1 2026 | Change at CER; Appendix 1 'Q2 2026 (\u20ac million) | Total sales | ...'",
"Q2 2026 press release Appendix 7 (currency)": "Actual average currency rates: Q2 2025 | Q2 2026 | Change; 'Euro/US Dollar | 1.134 | 1.163'"
},
"adjustments": {
"splits_applied": [],
"splits_note": "No share split in the periods covered.",
"adr_ratio": 0.5,
"adr_note": "Per-share figures are stated per American Depositary Share. The FY2025 Form 20-F cover page lists 'American Depositary Shares, each representing one half of one ordinary share', so each euro per-share amount was multiplied by 0.5 before conversion. Share counts are ordinary shares as filed.",
"fx": "Sanofi reports in euros. Every money figure was converted to US dollars: Q2 2026 and Q2 2025 flows at the average Euro/US Dollar rates stated in the Q2 2026 press release (1.163 and 1.134 US dollars per euro); all other periods at Federal Reserve (FRED) euro rates for the period's own dates, averages for income-statement and cash-flow figures and the period-end rate for balance-sheet figures. The rate used is recorded on each period under 'conversion'."
},
"annual": [
{
"fiscal_year": 2025,
"label": "FY2025",
"period_start": "2025-01-01",
"period_end": "2025-12-31",
"period_type": "fiscal year",
"source_accession": "0001628280-26-008403",
"accounting_basis": "IFRS as issued by the IASB and as endorsed by the European Union (audited, Form 20-F)",
"conversion": {
"currency": "EUR",
"average": {
"eur_per_usd": 0.884469,
"source": "FRED DEXUSEU, average of 250 daily rates 2025-01-01 to 2025-12-31"
},
"ads_ratio": 0.5,
"closing": {
"eur_per_usd": 0.852079,
"source": "FRED DEXUSEU, rate on 2025-12-31"
}
},
"income_statement": {
"net_sales": 49324509960,
"other_revenues": 3493621597,
"cost_of_sales": 14753484859,
"gross_profit": 38064646698,
"research_and_development_expenses": 8866336751,
"selling_and_general_expenses": 10789524562,
"other_operating_income": 1391795529,
"other_operating_expenses": 6393666708,
"amortization_of_intangible_assets": 2007984452,
"impairment_of_intangible_assets": 2533723624,
"fair_value_remeasurement_of_contingent_consideration": -117584675,
"restructuring_costs_and_similar_items": 1286647695,
"other_gains_and_losses_and_litigation": -288308578,
"operating_income": 7172665181,
"financial_expenses": 636540116,
"financial_income": 445465019,
"income_before_tax_and_equity_method_investments": 6981590084,
"income_tax_expense": 1179238617,
"share_of_profit_or_loss_from_equity_method_investments": -175246391,
"net_income_from_continuing_operations": 5627105077,
"net_income_from_discontinued_operations": 3249407271,
"net_income": 8876512348,
"net_income_attributable_to_noncontrolling_interests": 42963631,
"net_income_attributable_to_equity_holders_of_sanofi": 8833548717,
"weighted_average_basic_shares": 1220400000,
"diluted_shares": 1225600000,
"basic_eps_continuing_operations": 2.2895,
"basic_eps": 3.618,
"diluted_eps_continuing_operations": 2.2782,
"diluted_eps": 3.601,
"total_revenue_derived": 52818131557
},
"balance_sheet": {
"property_plant_and_equipment": 11797028210,
"goodwill": 48469684149,
"other_intangible_assets": 30819912238,
"total_non_current_assets": 112493090429,
"inventories": 11987151426,
"accounts_receivable": 9869976845,
"cash_and_cash_equivalents": 8986255969,
"assets_held_for_sale": 244108821,
"total_current_assets": 36325270309,
"total_assets": 148818360739,
"equity_attributable_to_equity_holders_of_sanofi": 83766880770,
"noncontrolling_interests": 391982434,
"total_equity": 84158863204,
"long_term_debt": 16721454231,
"non_current_lease_liabilities": 1721671347,
"total_non_current_liabilities": 31393802687,
"accounts_payable": 8638870339,
"current_lease_liabilities": 319219227,
"short_term_debt_and_current_portion_of_long_term_debt": 5095771636,
"total_current_liabilities": 33265694848,
"total_debt": 21948669079,
"total_liabilities_derived": 64659497535
},
"non_ifrs_measures": {
"net_debt": 12918989906
},
"cash_flow": {
"depreciation_amortization_and_impairment": 6419671012,
"net_cash_from_continuing_operating_activities": 11940497632,
"operating_cash_flow": 12154185166,
"capex": -4000140197,
"acquisitions_of_consolidated_undertakings_and_equity_method_investments": -10621061903,
"net_cash_from_investing_activities": -2766631730,
"dividends_paid_to_sanofi_shareholders": -5395327592,
"acquisitions_of_treasury_shares": -5687028036,
"net_cash_from_financing_activities": -9279013736,
"net_change_in_cash_and_cash_equivalents": 244214325,
"free_cash_flow_derived": 8154044969
},
"shareholder_returns": {
"dividend_per_share_paid": 2.216
}
},
{
"fiscal_year": 2024,
"label": "FY2024",
"period_start": "2024-01-01",
"period_end": "2024-12-31",
"period_type": "fiscal year",
"source_accession": "0001628280-26-008403",
"accounting_basis": "IFRS as issued by the IASB and as endorsed by the European Union (audited, Form 20-F)",
"conversion": {
"currency": "EUR",
"average": {
"eur_per_usd": 0.924215,
"source": "FRED DEXUSEU, average of 251 daily rates 2024-01-01 to 2024-12-31"
},
"ads_ratio": 0.5,
"closing": {
"eur_per_usd": 0.96609,
"source": "FRED DEXUSEU, rate on 2024-12-31"
}
},
"income_statement": {
"net_sales": 44449613997,
"other_revenues": 3467807815,
"cost_of_sales": 14287800999,
"gross_profit": 33629620813,
"research_and_development_expenses": 8000302960,
"selling_and_general_expenses": 9935999740,
"other_operating_income": 1178297258,
"other_operating_expenses": 4741321013,
"amortization_of_intangible_assets": 1892416808,
"impairment_of_intangible_assets": 268335831,
"fair_value_remeasurement_of_contingent_consideration": -103871935,
"restructuring_costs_and_similar_items": 1510471048,
"other_gains_and_losses_and_litigation": -508539680,
"operating_income": 7846659057,
"financial_expenses": 1160985269,
"financial_income": 561557646,
"income_before_tax_and_equity_method_investments": 7247231434,
"income_tax_expense": 1302727179,
"share_of_profit_or_loss_from_equity_method_investments": 64919959,
"net_income_from_continuing_operations": 6009424214,
"net_income_from_discontinued_operations": 69247956,
"net_income": 6078672170,
"net_income_attributable_to_noncontrolling_interests": 62755960,
"net_income_attributable_to_equity_holders_of_sanofi": 6015916210,
"weighted_average_basic_shares": 1251400000,
"diluted_shares": 1256100000,
"basic_eps_continuing_operations": 2.3804,
"basic_eps": 2.402,
"diluted_eps_continuing_operations": 2.375,
"diluted_eps": 2.3966,
"total_revenue_derived": 47917421812
},
"balance_sheet": {
"property_plant_and_equipment": 10445196617,
"goodwill": 44906789223,
"other_intangible_assets": 23423283545,
"total_non_current_assets": 93376393504,
"inventories": 9762030453,
"accounts_receivable": 7946464615,
"cash_and_cash_equivalents": 7702180956,
"assets_held_for_sale": 13962467265,
"total_current_assets": 44082849424,
"total_assets": 137459242928,
"equity_attributable_to_equity_holders_of_sanofi": 80227515035,
"noncontrolling_interests": 362285087,
"total_equity": 80589800122,
"long_term_debt": 12204867041,
"non_current_lease_liabilities": 1702739910,
"total_non_current_liabilities": 26683849331,
"accounts_payable": 7816041984,
"current_lease_liabilities": 270161165,
"short_term_debt_and_current_portion_of_long_term_debt": 4356736950,
"total_current_liabilities": 30185593475,
"total_debt": 16703412726,
"total_liabilities_derived": 56869442806
},
"non_ifrs_measures": {
"net_debt": 9079899388
},
"cash_flow": {
"depreciation_amortization_and_impairment": 3880049556,
"net_cash_from_continuing_operating_activities": 9312768133,
"operating_cash_flow": 9825635810,
"capex": -3456987822,
"acquisitions_of_consolidated_undertakings_and_equity_method_investments": -2056880704,
"net_cash_from_investing_activities": -4768370996,
"dividends_paid_to_sanofi_shareholders": -5089724793,
"acquisitions_of_treasury_shares": -326763794,
"net_cash_from_financing_activities": -6235562072,
"net_change_in_cash_and_cash_equivalents": -1373057135,
"free_cash_flow_derived": 6368647988
},
"shareholder_returns": {
"dividend_per_share_paid": 2.0342
}
},
{
"fiscal_year": 2023,
"label": "FY2023",
"period_start": "2023-01-01",
"period_end": "2023-12-31",
"period_type": "fiscal year",
"source_accession": "0001628280-26-008403",
"accounting_basis": "IFRS as issued by the IASB and as endorsed by the European Union (audited, Form 20-F)",
"presentation_note": "Income statement and cash flow figures for 2023 are as re-presented in the FY2025 Form 20-F, with the Opella consumer-health business shown as a discontinued operation.",
"conversion": {
"currency": "EUR",
"average": {
"eur_per_usd": 0.924504,
"source": "FRED DEXUSEU, average of 249 daily rates 2023-01-01 to 2023-12-31"
},
"ads_ratio": 0.5,
"closing": {
"eur_per_usd": 0.903996,
"source": "FRED DEXUSEU, rate on 2023-12-29 (last before 2023-12-31)"
}
},
"income_statement": {
"net_sales": 40905177263,
"other_revenues": 4111393785,
"cost_of_sales": 13659216185,
"gross_profit": 31357354863,
"research_and_development_expenses": 7038368682,
"selling_and_general_expenses": 9662478475,
"other_operating_income": 1058946203,
"other_operating_expenses": 3724159117,
"amortization_of_intangible_assets": 2067054334,
"impairment_of_intangible_assets": 969168332,
"fair_value_remeasurement_of_contingent_consideration": -100594481,
"restructuring_costs_and_similar_items": 1114110918,
"other_gains_and_losses_and_litigation": -212005573,
"operating_income": 7528361154,
"financial_expenses": 1398587783,
"financial_income": 631690074,
"income_before_tax_and_equity_method_investments": 6761463444,
"income_tax_expense": 1100049324,
"share_of_profit_or_loss_from_equity_method_investments": -147105908,
"net_income_from_continuing_operations": 5514308213,
"net_income_from_discontinued_operations": 365601447,
"net_income": 5879909660,
"net_income_attributable_to_noncontrolling_interests": 38939799,
"net_income_attributable_to_equity_holders_of_sanofi": 5840969861,
"weighted_average_basic_shares": 1251700000,
"diluted_shares": 1256400000,
"basic_eps_continuing_operations": 2.1958,
"basic_eps": 2.331,
"diluted_eps_continuing_operations": 2.1904,
"diluted_eps": 2.3256,
"total_revenue_derived": 45016571048
},
"balance_sheet": {
"property_plant_and_equipment": 11238987783,
"goodwill": 54650684295,
"other_intangible_assets": 26901667706,
"total_non_current_assets": 105967283041,
"inventories": 10692525188,
"accounts_receivable": 9328581100,
"cash_and_cash_equivalents": 9634998385,
"assets_held_for_sale": 16592994,
"total_current_assets": 33927141271,
"total_assets": 139894424312,
"equity_attributable_to_equity_holders_of_sanofi": 81903017270,
"noncontrolling_interests": 346240470,
"total_equity": 82249257740,
"long_term_debt": 15870645445,
"non_current_lease_liabilities": 1941380272,
"total_non_current_liabilities": 30867393219,
"accounts_payable": 8106230559,
"current_lease_liabilities": 304204886,
"short_term_debt_and_current_portion_of_long_term_debt": 2262178151,
"total_current_liabilities": 26777773353,
"total_debt": 18286585339,
"total_liabilities_derived": 57645166572
},
"non_ifrs_measures": {
"net_debt": 8620613366
},
"cash_flow": {
"depreciation_amortization_and_impairment": 4790676947,
"net_cash_from_continuing_operating_activities": 10028079922,
"operating_cash_flow": 11095679413,
"capex": -3143307114,
"acquisitions_of_consolidated_undertakings_and_equity_method_investments": -2742010851,
"net_cash_from_investing_activities": -6706298729,
"dividends_paid_to_sanofi_shareholders": -4817718474,
"acquisitions_of_treasury_shares": -641425024,
"net_cash_from_financing_activities": -8709535059,
"net_change_in_cash_and_cash_equivalents": -4354767529,
"free_cash_flow_derived": 7952372299
},
"shareholder_returns": {
"dividend_per_share_paid": 1.9254
}
}
],
"quarterly": [
{
"fiscal_year": 2026,
"fiscal_quarter": 2,
"label": "Q2 2026",
"period_start": "2026-04-01",
"period_end": "2026-06-30",
"period_type": "three months",
"source_accession": "0001121404-26-000008",
"accounting_basis": "IFRS consolidated income statement for the quarter as printed in the Q2 2026 results press release (unaudited, furnished on Form 6-K)",
"conversion": {
"currency": "EUR",
"average": {
"eur_per_usd": 0.859845,
"source": "Q2 2026 results press release furnished on Form 6-K (accession 0001121404-26-000008), Appendix 7 'Actual average currency rates': 'Euro/US Dollar | 1.134 | 1.163' for Q2 2025 and Q2 2026; expressed here as euros per US dollar (1/1.163)"
},
"ads_ratio": 0.5,
"closing": {
"eur_per_usd": 0.875887,
"source": "FRED DEXUSEU, rate on 2026-06-30"
}
},
"income_statement": {
"net_sales": 13487314574,
"other_revenues": 817589217,
"cost_of_sales": 3508771930,
"gross_profit": 10796131861,
"research_and_development_expenses": 2596979688,
"selling_and_general_expenses": 2866795760,
"other_operating_income": 602434160,
"other_operating_expenses": 2284132605,
"amortization_of_intangible_assets": 641976170,
"impairment_of_intangible_assets": 1199053318,
"fair_value_remeasurement_of_contingent_consideration": -83736022,
"restructuring_costs_and_similar_items": 516372137,
"other_gains_and_losses_and_litigation": 8141002,
"operating_income": 1217661323,
"financial_expenses": 333781088,
"financial_income": 89551024,
"income_before_tax_and_equity_method_investments": 973431258,
"income_tax_expense": 524513139,
"share_of_profit_or_loss_from_equity_method_investments": -10467003,
"net_income_from_continuing_operations": 438451116,
"net_income_from_discontinued_operations": 0.0,
"net_income": 438451116,
"net_income_attributable_to_noncontrolling_interests": 39542010,
"net_income_attributable_to_equity_holders_of_sanofi": 398909106,
"weighted_average_basic_shares": 1196600000,
"basic_eps_continuing_operations": 0.1686,
"basic_eps": 0.1686,
"total_revenue_derived": 14304903791
},
"balance_sheet": {
"property_plant_and_equipment": 11832576577,
"goodwill": 47898872800,
"other_intangible_assets": 30094064645,
"total_non_current_assets": 111359113676,
"inventories": 12703693513,
"accounts_receivable": 9948771931,
"cash_and_cash_equivalents": 7249793638,
"assets_held_for_sale": 635926781,
"total_current_assets": 35988660638,
"total_assets": 147347774313,
"equity_attributable_to_equity_holders_of_sanofi": 79013617053,
"noncontrolling_interests": 411011923,
"total_equity": 79424628976,
"long_term_debt": 16721335058,
"non_current_lease_liabilities": 1914630540,
"total_non_current_liabilities": 31468671187,
"accounts_payable": 8163153466,
"current_lease_liabilities": 259165851,
"short_term_debt_and_current_portion_of_long_term_debt": 8021582693,
"total_current_liabilities": 36454474150,
"total_debt": 24995233403,
"total_liabilities_derived": 67923145337
},
"non_ifrs_measures": {
"net_debt": 17711188772,
"business_operating_income": 3827434014,
"business_net_income": 2908663771,
"business_eps": 1.2153,
"company_defined_free_cash_flow": 3105210823
},
"net_sales_by_geography": {
"united_states": 7378073955,
"europe": 2489983660,
"rest_of_world": 3619256959,
"of_which_china": 786188208
},
"net_sales_by_product": {
"dupixent": 5994103588
},
"balance_sheet_source_accession": "0001628280-26-050803",
"balance_sheet_note": "Balance sheet as of June 30, 2026, from the condensed half-year consolidated financial statements; net debt from note B.9 of the same statements.",
"non_ifrs_source_note": "Business measures and free cash flow from the Q2 2026 results press release; net debt from note B.9 of the half-year financial statements."
},
{
"fiscal_year": 2025,
"fiscal_quarter": 2,
"label": "Q2 2025",
"period_start": "2025-04-01",
"period_end": "2025-06-30",
"period_type": "three months",
"source_accession": "0001121404-26-000008",
"accounting_basis": "IFRS consolidated income statement for the quarter as printed in the Q2 2026 results press release (unaudited, furnished on Form 6-K)",
"conversion": {
"currency": "EUR",
"average": {
"eur_per_usd": 0.881834,
"source": "Q2 2026 results press release furnished on Form 6-K (accession 0001121404-26-000008), Appendix 7 'Actual average currency rates': 'Euro/US Dollar | 1.134 | 1.163' for Q2 2025 and Q2 2026; expressed here as euros per US dollar (1/1.134)"
},
"ads_ratio": 0.5
},
"income_statement": {
"net_sales": 11333198765,
"other_revenues": 840294205,
"cost_of_sales": 3394062828,
"gross_profit": 8779430142,
"research_and_development_expenses": 2164806528,
"selling_and_general_expenses": 2590056632,
"other_operating_income": 229068056,
"other_operating_expenses": 1494612365,
"amortization_of_intangible_assets": 428652105,
"impairment_of_intangible_assets": 209790051,
"fair_value_remeasurement_of_contingent_consideration": -58968014,
"restructuring_costs_and_similar_items": 368550090,
"other_gains_and_losses_and_litigation": -22680006,
"operating_income": 1670382408,
"financial_expenses": 167832041,
"financial_income": 111132027,
"income_before_tax_and_equity_method_investments": 1613682394,
"income_tax_expense": 260820064,
"share_of_profit_or_loss_from_equity_method_investments": 48762012,
"net_income_from_continuing_operations": 1401624342,
"net_income_from_discontinued_operations": 3069738749,
"net_income": 4471363091,
"net_income_attributable_to_noncontrolling_interests": 4536001,
"net_income_attributable_to_equity_holders_of_sanofi": 4466827090,
"weighted_average_basic_shares": 1217100000,
"basic_eps_continuing_operations": 0.5783,
"basic_eps": 1.8371,
"total_revenue_derived": 12173492970
},
"non_ifrs_measures": {
"business_operating_income": 2790774681,
"business_net_income": 2199960537,
"business_eps": 0.9015
}
}
],
"year_to_date": {
"label": "H1 2026 (six months ended June 30, 2026)",
"period_start": "2026-01-01",
"period_end": "2026-06-30",
"period_type": "six months",
"source_accession": "0001628280-26-050803",
"accounting_basis": "IAS 34 condensed half-year consolidated financial statements (unaudited, furnished on Form 6-K)",
"prior_year_comparative": {
"label": "H1 2025 (six months ended June 30, 2025)",
"period_start": "2025-01-01",
"period_end": "2025-06-30",
"period_type": "six months",
"source_accession": "0001628280-26-050803",
"accounting_basis": "IAS 34 condensed half-year consolidated financial statements (unaudited, furnished on Form 6-K)",
"conversion": {
"currency": "EUR",
"average": {
"eur_per_usd": 0.913837,
"source": "FRED DEXUSEU, average of 124 daily rates 2025-01-01 to 2025-06-30"
},
"ads_ratio": 0.5
},
"income_statement": {
"net_sales": 21764275248,
"other_revenues": 1588904805,
"cost_of_sales": 6435502174,
"gross_profit": 16917677879,
"research_and_development_expenses": 4067464986,
"selling_and_general_expenses": 4930857472,
"other_operating_income": 583255001,
"other_operating_expenses": 2709454750,
"amortization_of_intangible_assets": 850261042,
"impairment_of_intangible_assets": 229800282,
"fair_value_remeasurement_of_contingent_consideration": -66751510,
"restructuring_costs_and_similar_items": 470543434,
"other_gains_and_losses_and_litigation": -62374362,
"operating_income": 4113425042,
"financial_expenses": 395037627,
"financial_income": 201348818,
"income_before_tax_and_equity_method_investments": 3919736233,
"income_tax_expense": 778038097,
"share_of_profit_or_loss_from_equity_method_investments": 93014400,
"net_income_from_continuing_operations": 3234712536,
"net_income_from_discontinued_operations": 3152641007,
"net_income": 6387353543,
"net_income_attributable_to_noncontrolling_interests": 27357176,
"net_income_attributable_to_equity_holders_of_sanofi": 6359996367,
"weighted_average_basic_shares": 1225500000,
"diluted_shares": 1230700000,
"basic_eps_continuing_operations": 1.3131,
"basic_eps": 2.5935,
"diluted_eps_continuing_operations": 1.3077,
"diluted_eps": 2.5825,
"total_revenue_derived": 23353180053
},
"cash_flow": {
"depreciation_amortization_and_impairment": 1946736672,
"net_cash_from_continuing_operating_activities": 3684464516,
"operating_cash_flow": 3890190483,
"capex": -1553887619,
"acquisitions_of_consolidated_undertakings_and_equity_method_investments": -588726436,
"net_cash_from_investing_activities": 9549843134,
"dividends_paid_to_sanofi_shareholders": -5221937829,
"acquisitions_of_treasury_shares": -4380431083,
"net_cash_from_financing_activities": -4912254592,
"net_change_in_cash_and_cash_equivalents": 8664564906,
"free_cash_flow_derived": 2336302864
},
"shareholder_returns": {
"dividend_per_share_paid": 2.1448
},
"non_ifrs_measures": {
"business_operating_income": 5868661479,
"business_net_income": 4543479855,
"business_eps": 1.8548,
"company_defined_free_cash_flow": 2689757583
}
},
"conversion": {
"currency": "EUR",
"average": {
"eur_per_usd": 0.857185,
"source": "FRED DEXUSEU, average of 124 daily rates 2026-01-01 to 2026-06-30"
},
"ads_ratio": 0.5
},
"income_statement": {
"net_sales": 25789065371,
"other_revenues": 1677584185,
"cost_of_sales": 7180480293,
"gross_profit": 20286169263,
"research_and_development_expenses": 4643105047,
"selling_and_general_expenses": 5590391806,
"other_operating_income": 933287447,
"other_operating_expenses": 4008469584,
"amortization_of_intangible_assets": 1268104318,
"impairment_of_intangible_assets": 1202774197,
"fair_value_remeasurement_of_contingent_consideration": -43164544,
"restructuring_costs_and_similar_items": 656801041,
"other_gains_and_losses_and_litigation": -110827884,
"operating_income": 3695818289,
"financial_expenses": 542473328,
"financial_income": 159825475,
"income_before_tax_and_equity_method_investments": 3313170436,
"income_tax_expense": 1016116708,
"share_of_profit_or_loss_from_equity_method_investments": 2333219,
"net_income_from_continuing_operations": 2299386947,
"net_income_from_discontinued_operations": 30331842,
"net_income": 2329718789,
"net_income_attributable_to_noncontrolling_interests": 46664372,
"net_income_attributable_to_equity_holders_of_sanofi": 2283054416,
"weighted_average_basic_shares": 1200400000,
"diluted_shares": 1205500000,
"basic_eps_continuing_operations": 0.9391,
"basic_eps": 0.9508,
"diluted_eps_continuing_operations": 0.9333,
"diluted_eps": 0.945,
"total_revenue_derived": 27466649556
},
"cash_flow": {
"depreciation_amortization_and_impairment": 3359834808,
"net_cash_from_continuing_operating_activities": 5416567019,
"operating_cash_flow": 5416567019,
"capex": -1511925664,
"acquisitions_of_consolidated_undertakings_and_equity_method_investments": -1642585906,
"net_cash_from_investing_activities": -3083348402,
"dividends_paid_to_sanofi_shareholders": -5743217625,
"acquisitions_of_treasury_shares": -1177108792,
"net_cash_from_financing_activities": -3887142216,
"net_change_in_cash_and_cash_equivalents": -1531758022,
"free_cash_flow_derived": 3904641355
},
"shareholder_returns": {
"dividend_per_share_paid": 2.4032
},
"non_ifrs_measures": {
"business_operating_income": 7300641052,
"business_net_income": 5558893354,
"business_eps": 2.3157,
"company_defined_free_cash_flow": 4344453064
}
},
"trailing_twelve_months": {
"label": "Twelve months ended June 30, 2026 (derived)",
"period_start": "2025-07-01",
"period_end": "2026-06-30",
"period_type": "trailing twelve months",
"source_accession": "0001628280-26-050803",
"sources": {
"FY2025": "0001628280-26-008403",
"H1 2026 and H1 2025": "0001628280-26-050803"
},
"derivation": "FY2025 (Form 20-F) plus H1 2026 less H1 2025 (both from the half-year financial statements furnished on Form 6-K), computed in euros and then converted at the average rate for the twelve months",
"conversion": {
"currency": "EUR",
"average": {
"eur_per_usd": 0.85727,
"source": "FRED DEXUSEU, average of 250 daily rates 2025-07-01 to 2026-06-30"
}
},
"income_statement": {
"net_sales": 53475567791,
"other_revenues": 3588134427,
"total_revenue_derived": 57063702218,
"cost_of_sales": 15541194723,
"gross_profit": 41522507495,
"operating_income": 6710837892,
"net_income": 4678805977,
"net_income_attributable_to_equity_holders_of_sanofi": 4616981814
},
"cash_flow": {
"operating_cash_flow": 13808951672,
"capex": -3982409276,
"free_cash_flow_derived": 9826542396
}
},
"notes": [
"Annual figures (FY2025, FY2024, FY2023) are from Sanofi's FY2025 Form 20-F (accession 0001628280-26-008403), which prints three years of income statement, balance sheet and cash flow.",
"The six-month figures (H1 2026, with H1 2025 as comparative) and the June 30, 2026 balance sheet are from the condensed half-year consolidated financial statements furnished as Exhibit 99.1 to Form 6-K accession 0001628280-26-050803. Those statements present six-month columns only.",
"The three-month Q2 2026 and Q2 2025 income statements are from Appendix 3 of the Q2 2026 results press release, furnished the same day on Form 6-K accession 0001121404-26-000008. Its H1 columns match the half-year financial statements line for line.",
"The press release prints basic earnings per share and the basic average share count for the quarters but no diluted figures, so the quarterly entries carry basic EPS only. Diluted EPS is given for the half-years and full years.",
"Expense lines in the income statement (cost of sales, research and development, selling and general, other operating expenses, amortization and impairment of intangible assets, restructuring costs, financial expenses and income tax expense) are stated as positive amounts; the statements print them in parentheses. Lines that can be either sign (fair value remeasurement of contingent consideration; other gains and losses, and litigation; share of profit/loss from equity-method investments) keep the filing's sign. Cash flow lines keep the filing's sign, with outflows negative.",
"total_revenue_derived is net sales plus other revenues. Sanofi prints no total revenue line, but its gross profit is net sales plus other revenues less cost of sales. Net sales is the top line Sanofi reports and comments on.",
"total_liabilities_derived is non-current liabilities plus current liabilities, both printed on the balance sheet. Sanofi prints no total liabilities line.",
"total_debt and net_debt follow Sanofi's own definitions (note D.17.1 of the Form 20-F; note B.9 of the half-year statements). Total debt is long-term debt, short-term debt and interest-rate and currency derivatives used to manage debt. Net debt subtracts cash and cash equivalents and related derivatives. Both exclude lease liabilities. Net debt is a non-IFRS measure. The press release states net debt at January 1, 2026 as \u20ac10,988 million after the IFRS 9 amendment that applied from that date; the December 31, 2025 figure reported here (\u20ac11,008 million) is the one printed in both sets of financial statements.",
"free_cash_flow_derived is net cash provided by operating activities less 'Acquisitions of property, plant and equipment and intangible assets', the line Sanofi prints, which includes intangible assets such as licences. Operating cash flow includes the discontinued Opella business where the statements show it (FY2023-FY2025 and H1 2025). company_defined_free_cash_flow is Sanofi's own non-IFRS free cash flow (H1 2026 \u20ac3,724 million; Q2 2026 \u20ac2,670 million). It starts from business net income and also deducts restructuring payments and acquisitions up to \u20ac500 million per transaction, net of disposal proceeds, so the two measures differ.",
"Business operating income, business net income and business EPS are Sanofi's non-IFRS measures, taken from the press release. Business EPS is stated per ADS, like every per-share figure here.",
"Sanofi's Opella consumer-health business is a discontinued operation. Its 2025 results, including the gain on the transaction, appear in net income from discontinued operations: \u20ac2,874 million in FY2025, \u20ac2,881 million in H1 2025 and \u20ac2,707 million in Q2 2025. The FY2023 income statement and cash flow are as re-presented in the FY2025 Form 20-F on that basis.",
"dividend_per_share_paid is the dividend paid during the period out of the prior year's earnings, as printed in the statements of changes in equity (\u20ac4.12 per share in H1 2026; \u20ac3.92 in 2025; \u20ac3.76 in 2024; \u20ac3.56 in 2023), stated per ADS.",
"Q2 2026 net sales by geography and Dupixent sales are from the press release. For the year-ago quarter the release gives only growth rates for these lines, not amounts, so no Q2 2025 breakdown is shown.",
"The trailing twelve months to June 30, 2026 are derived as FY2025 plus H1 2026 less H1 2025, computed in euros from the printed figures and then converted."
],
"uncertainties": [
"No three-month cash flow is shown for Q2 2026 or Q2 2025. The half-year statements and the press release print only six-month cash flows, and the first-quarter 2026 report is not among the filings for this period, so the quarter cannot be isolated. The Q2 2026 free cash flow shown is Sanofi's own non-IFRS figure from the press release highlights table.",
"US-dollar amounts depend on the exchange rate used. The quarters use the rates the press release states and the half-years use Federal Reserve averages, so the US-dollar Q2 figure and the US-dollar H1 figure do not difference exactly to a first quarter."
],
"headline": {
"period": "Q2 FY2026",
"period_end_words": "June 30, 2026",
"metrics": [
{
"label": "Net sales",
"format": "usd",
"value": 13487314574,
"text": "$13.49 billion",
"exact": "$13,487,314,574",
"compact": "$13.49B",
"abs": "$13.49 billion",
"prior_value": 11333198765,
"prior": "$11.33 billion",
"priorabs": "$11.33 billion",
"yoy": "up 19.0%",
"source": {
"array": "quarterly",
"field": "income_statement.net_sales",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0001121404-26-000008",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0001121404-26-000008",
"gap_days": 365
}
},
{
"label": "Net income",
"format": "usd",
"value": 398909106,
"text": "$398.91 million",
"exact": "$398,909,106",
"compact": "$398.91M",
"abs": "$398.91 million",
"prior_value": 4466827090,
"prior": "$4.47 billion",
"priorabs": "$4.47 billion",
"yoy": "down 91.1%",
"source": {
"array": "quarterly",
"field": "income_statement.net_income_attributable_to_equity_holders_of_sanofi",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0001121404-26-000008",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0001121404-26-000008",
"gap_days": 365
}
},
{
"label": "Basic EPS per ADS",
"format": "eps",
"value": 0.1686,
"text": "$0.17",
"exact": "$0.17",
"compact": "$0.17",
"abs": "$0.17",
"prior_value": 1.8371,
"prior": "$1.84",
"priorabs": "$1.84",
"yoy": "down 90.8%",
"source": {
"array": "quarterly",
"field": "income_statement.basic_eps",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0001121404-26-000008",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0001121404-26-000008",
"gap_days": 365
}
},
{
"label": "Business EPS per ADS",
"format": "eps",
"value": 1.2153,
"text": "$1.22",
"exact": "$1.22",
"compact": "$1.22",
"abs": "$1.22",
"prior_value": 0.9015,
"prior": "$0.90",
"priorabs": "$0.90",
"yoy": "up 34.8%",
"source": {
"array": "quarterly",
"field": "non_ifrs_measures.business_eps",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0001121404-26-000008",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0001121404-26-000008",
"gap_days": 365
}
},
{
"label": "Dupixent sales",
"format": "usd",
"value": 5994103588,
"text": "$5.99 billion",
"exact": "$5,994,103,588",
"compact": "$5.99B",
"abs": "$5.99 billion",
"prior_value": null,
"prior": null,
"priorabs": null,
"yoy": null,
"source": {
"array": "quarterly",
"field": "net_sales_by_product.dupixent",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0001121404-26-000008"
}
}
],
"summary": "Sanofi reported net sales of $13.49 billion for Q2 FY2026, the quarter ended June 30, 2026, up 19.0% from a year earlier in US dollar terms, with its largest medicine, Dupixent, contributing $5.99 billion. Net income attributable to Sanofi shareholders was $398.91 million, down 91.1%, and basic earnings were $0.17 per ADS against $1.84, mainly because the quarter carried an impairment writing off the drug candidate amlitelimab while the year-earlier quarter included the gain on the sale of the Opella consumer health business. On Sanofi's non-IFRS business basis, which excludes those items, earnings were $1.22 per ADS, up 34.8% in US dollar terms.",
"qa": [
{
"q": "How much revenue did Sanofi make in Q2 FY2026?",
"a": "Sanofi reported net sales of $13.49 billion for Q2 FY2026, the quarter ended June 30, 2026. That is up 19.0% in US dollar terms from $11.33 billion in the same quarter a year earlier."
},
{
"q": "Why did Sanofi's net income fall in Q2 FY2026?",
"a": "Sanofi's net income attributable to shareholders was $398.91 million in Q2 FY2026, down 91.1% from $4.47 billion a year earlier. The quarter included an impairment writing off the drug candidate amlitelimab, and the year-earlier quarter included the gain on the sale of the Opella consumer health business."
},
{
"q": "What were Sanofi's earnings per ADS in Q2 FY2026?",
"a": "Sanofi's basic earnings per American Depositary Share were $0.17 in Q2 FY2026, against $1.84 a year earlier. Business EPS, Sanofi's non-IFRS measure that excludes impairments of acquired intangibles and discontinued operations, was $1.22 per ADS, up 34.8% in US dollar terms from $0.90."
},
{
"q": "How much did Dupixent sell in Q2 FY2026?",
"a": "Dupixent, Sanofi's largest medicine, had net sales of $5.99 billion in Q2 FY2026, the quarter ended June 30, 2026, out of total Sanofi net sales of $13.49 billion."
}
]
},
"company_details": {
"Name": "Sanofi",
"Ticker": "SNY",
"CIK": "0001121404",
"Exchange": "Nasdaq",
"State": "France",
"Incorporation": "France",
"SIC": "2834",
"Office": "Life Sciences",
"Industry": "Pharmaceutical Preparations"
},
"next_filing": {
"predicted_date": "2026-10-23",
"predicted_type": "6-K"
},
"fiscal_period": {
"fiscal_year": 2026,
"fiscal_period": "Q2",
"tag": "FY26Q2",
"period_end": "2026-06-30",
"form": "6-K",
"accession": "0001628280-26-050803",
"fiscal_year_end": "1231",
"source": "derived"
},
"source_filings": [
{
"role": "annual",
"current": false,
"form": "20-F",
"fiscal_year": 2025,
"fiscal_period": "FY",
"tag": "FY25",
"period_end": "2025-12-31",
"filed": "2026-02-17",
"accession": "0001628280-26-008403",
"url": "https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm",
"source": "reported"
},
{
"role": "quarterly",
"current": true,
"form": "6-K",
"fiscal_year": 2026,
"fiscal_period": "Q2",
"tag": "FY26Q2",
"period_end": "2026-06-30",
"filed": "2026-07-30",
"accession": "0001628280-26-050803",
"url": "https://www.sec.gov/Archives/edgar/data/1121404/000162828026050803/0001628280-26-050803-index.htm",
"source": "derived"
}
],
"figure_sources": {
"about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '<document>#<anchor>', and the link is documents[<document>] + '#<anchor>': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release. A figure this file converted to US dollars links to the number as the filing prints it, in the filing's own currency: that number at its period's conversion rate (and ADS ratio, for a per-share figure) is the figure.",
"documents": {
"d1": "https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm"
},
"annual": [
{
"period_end": "2025-12-31",
"income_statement": {
"net_sales": "d1#f-178",
"other_revenues": "d1#f-181",
"cost_of_sales": "d1#f-184",
"gross_profit": "d1#f-187",
"research_and_development_expenses": "d1#f-190",
"selling_and_general_expenses": "d1#f-193",
"other_operating_income": "d1#f-196",
"other_operating_expenses": "d1#f-199",
"amortization_of_intangible_assets": "d1#f-202",
"impairment_of_intangible_assets": "d1#f-205",
"fair_value_remeasurement_of_contingent_consideration": "d1#f-208",
"restructuring_costs_and_similar_items": "d1#f-211",
"other_gains_and_losses_and_litigation": "d1#f-214",
"operating_income": "d1#f-217",
"financial_expenses": "d1#f-220",
"financial_income": "d1#f-223",
"income_before_tax_and_equity_method_investments": "d1#f-226",
"income_tax_expense": "d1#f-229",
"share_of_profit_or_loss_from_equity_method_investments": "d1#f-232",
"net_income_from_continuing_operations": "d1#f-235",
"net_income_from_discontinued_operations": "d1#f-238",
"net_income": "d1#f-241",
"net_income_attributable_to_noncontrolling_interests": "d1#f-244",
"net_income_attributable_to_equity_holders_of_sanofi": "d1#f-556",
"weighted_average_basic_shares": "d1#f-250",
"diluted_shares": "d1#f-253",
"basic_eps_continuing_operations": "d1#f-256",
"basic_eps": "d1#f-262",
"diluted_eps_continuing_operations": "d1#f-265",
"diluted_eps": "d1#f-271"
},
"balance_sheet": {
"property_plant_and_equipment": "d1#f-70",
"goodwill": "d1#f-76",
"other_intangible_assets": "d1#f-1454",
"total_non_current_assets": "d1#f-94",
"inventories": "d1#f-97",
"accounts_receivable": "d1#f-100",
"cash_and_cash_equivalents": "d1#f-109",
"assets_held_for_sale": "d1#f-112",
"total_current_assets": "d1#f-115",
"total_assets": "d1#f-118",
"equity_attributable_to_equity_holders_of_sanofi": "d1#f-121",
"noncontrolling_interests": "d1#f-124",
"total_equity": "d1#f-127",
"long_term_debt": "d1#f-130",
"non_current_lease_liabilities": "d1#f-133",
"total_non_current_liabilities": "d1#f-148",
"accounts_payable": "d1#f-151",
"current_lease_liabilities": "d1#f-163",
"short_term_debt_and_current_portion_of_long_term_debt": "d1#f-166",
"total_current_liabilities": "d1#f-172",
"total_debt": "d1#f-2511"
},
"non_ifrs_measures": {
"net_debt": "d1#f-2520"
},
"cash_flow": {
"depreciation_amortization_and_impairment": "d1#f-568",
"net_cash_from_continuing_operating_activities": "d1#f-604",
"operating_cash_flow": "d1#f-610",
"capex": "d1#f-613",
"acquisitions_of_consolidated_undertakings_and_equity_method_investments": "d1#f-616",
"net_cash_from_investing_activities": "d1#f-640",
"dividends_paid_to_sanofi_shareholders": "d1#f-646",
"acquisitions_of_treasury_shares": "d1#f-667",
"net_cash_from_financing_activities": "d1#f-676",
"net_change_in_cash_and_cash_equivalents": "d1#f-685"
},
"shareholder_returns": {
"dividend_per_share_paid": "d1#f-500"
}
},
{
"period_end": "2024-12-31",
"income_statement": {
"net_sales": "d1#f-179",
"other_revenues": "d1#f-182",
"cost_of_sales": "d1#f-185",
"gross_profit": "d1#f-188",
"research_and_development_expenses": "d1#f-191",
"selling_and_general_expenses": "d1#f-194",
"other_operating_income": "d1#f-197",
"other_operating_expenses": "d1#f-200",
"amortization_of_intangible_assets": "d1#f-203",
"impairment_of_intangible_assets": "d1#f-206",
"fair_value_remeasurement_of_contingent_consideration": "d1#f-209",
"restructuring_costs_and_similar_items": "d1#f-212",
"other_gains_and_losses_and_litigation": "d1#f-215",
"operating_income": "d1#f-218",
"financial_expenses": "d1#f-221",
"financial_income": "d1#f-224",
"income_before_tax_and_equity_method_investments": "d1#f-227",
"income_tax_expense": "d1#f-230",
"share_of_profit_or_loss_from_equity_method_investments": "d1#f-233",
"net_income_from_continuing_operations": "d1#f-236",
"net_income_from_discontinued_operations": "d1#f-239",
"net_income": "d1#f-242",
"net_income_attributable_to_noncontrolling_interests": "d1#f-245",
"net_income_attributable_to_equity_holders_of_sanofi": "d1#f-557",
"weighted_average_basic_shares": "d1#f-251",
"diluted_shares": "d1#f-254",
"basic_eps_continuing_operations": "d1#f-257",
"basic_eps": "d1#f-263",
"diluted_eps_continuing_operations": "d1#f-266",
"diluted_eps": "d1#f-272"
},
"balance_sheet": {
"property_plant_and_equipment": "d1#f-71",
"goodwill": "d1#f-77",
"other_intangible_assets": "d1#f-1450",
"total_non_current_assets": "d1#f-95",
"inventories": "d1#f-98",
"accounts_receivable": "d1#f-101",
"cash_and_cash_equivalents": "d1#f-110",
"assets_held_for_sale": "d1#f-113",
"total_current_assets": "d1#f-116",
"total_assets": "d1#f-119",
"equity_attributable_to_equity_holders_of_sanofi": "d1#f-122",
"noncontrolling_interests": "d1#f-125",
"total_equity": "d1#f-128",
"long_term_debt": "d1#f-131",
"non_current_lease_liabilities": "d1#f-134",
"total_non_current_liabilities": "d1#f-149",
"accounts_payable": "d1#f-152",
"current_lease_liabilities": "d1#f-164",
"short_term_debt_and_current_portion_of_long_term_debt": "d1#f-167",
"total_current_liabilities": "d1#f-173",
"total_debt": "d1#f-2512"
},
"non_ifrs_measures": {
"net_debt": "d1#f-2521"
},
"cash_flow": {
"depreciation_amortization_and_impairment": "d1#f-569",
"net_cash_from_continuing_operating_activities": "d1#f-605",
"operating_cash_flow": "d1#f-611",
"capex": "d1#f-614",
"acquisitions_of_consolidated_undertakings_and_equity_method_investments": "d1#f-617",
"net_cash_from_investing_activities": "d1#f-641",
"dividends_paid_to_sanofi_shareholders": "d1#f-647",
"acquisitions_of_treasury_shares": "d1#f-434",
"net_cash_from_financing_activities": "d1#f-677",
"net_change_in_cash_and_cash_equivalents": "d1#f-686"
},
"shareholder_returns": {
"dividend_per_share_paid": "d1#f-425"
}
},
{
"period_end": "2023-12-31",
"income_statement": {
"net_sales": "d1#f-180",
"other_revenues": "d1#f-183",
"cost_of_sales": "d1#f-186",
"gross_profit": "d1#f-189",
"research_and_development_expenses": "d1#f-192",
"selling_and_general_expenses": "d1#f-195",
"other_operating_income": "d1#f-198",
"other_operating_expenses": "d1#f-201",
"amortization_of_intangible_assets": "d1#f-204",
"impairment_of_intangible_assets": "d1#f-207",
"fair_value_remeasurement_of_contingent_consideration": "d1#f-210",
"restructuring_costs_and_similar_items": "d1#f-213",
"other_gains_and_losses_and_litigation": "d1#f-216",
"operating_income": "d1#f-219",
"financial_expenses": "d1#f-222",
"financial_income": "d1#f-225",
"income_before_tax_and_equity_method_investments": "d1#f-228",
"income_tax_expense": "d1#f-231",
"share_of_profit_or_loss_from_equity_method_investments": "d1#f-234",
"net_income_from_continuing_operations": "d1#f-237",
"net_income_from_discontinued_operations": "d1#f-240",
"net_income": "d1#f-243",
"net_income_attributable_to_noncontrolling_interests": "d1#f-246",
"net_income_attributable_to_equity_holders_of_sanofi": "d1#f-558",
"weighted_average_basic_shares": "d1#f-252",
"diluted_shares": "d1#f-255",
"basic_eps_continuing_operations": "d1#f-258",
"basic_eps": "d1#f-264",
"diluted_eps_continuing_operations": "d1#f-267",
"diluted_eps": "d1#f-273"
},
"balance_sheet": {
"property_plant_and_equipment": "d1#f-72",
"goodwill": "d1#f-78",
"other_intangible_assets": "d1#f-1446",
"total_non_current_assets": "d1#f-96",
"inventories": "d1#f-99",
"accounts_receivable": "d1#f-102",
"cash_and_cash_equivalents": "d1#f-111",
"assets_held_for_sale": "d1#f-114",
"total_current_assets": "d1#f-117",
"total_assets": "d1#f-120",
"equity_attributable_to_equity_holders_of_sanofi": "d1#f-123",
"noncontrolling_interests": "d1#f-126",
"total_equity": "d1#f-129",
"long_term_debt": "d1#f-132",
"non_current_lease_liabilities": "d1#f-135",
"total_non_current_liabilities": "d1#f-150",
"accounts_payable": "d1#f-153",
"current_lease_liabilities": "d1#f-165",
"short_term_debt_and_current_portion_of_long_term_debt": "d1#f-168",
"total_current_liabilities": "d1#f-174",
"total_debt": "d1#f-2513"
},
"non_ifrs_measures": {
"net_debt": "d1#f-2522"
},
"cash_flow": {
"depreciation_amortization_and_impairment": "d1#f-570",
"net_cash_from_continuing_operating_activities": "d1#f-606",
"operating_cash_flow": "d1#f-612",
"capex": "d1#f-615",
"acquisitions_of_consolidated_undertakings_and_equity_method_investments": "d1#f-618",
"net_cash_from_investing_activities": "d1#f-642",
"dividends_paid_to_sanofi_shareholders": "d1#f-648",
"acquisitions_of_treasury_shares": "d1#f-363",
"net_cash_from_financing_activities": "d1#f-678",
"net_change_in_cash_and_cash_equivalents": "d1#f-687"
},
"shareholder_returns": {
"dividend_per_share_paid": "d1#f-354"
}
}
]
}
}